Strategies for Progress

  • Christopher Kwesi O. Williams


The future of cancer and HIV/AIDS control in low- and middle-income countries (LMICs) lies in strategic international collaboration for opportunities in global equity in health, so as to mitigate high rates of premature death and suffering. This goal should be attainable through successful performance of the United Nations initiatives, including the Sustainable Development Goals, and performing in concert with funding agencies, such as the Global Fund, and health care promoting agencies including the Global Alliance for Vaccine Development, the United States National Institutes of Health and its subsidiaries, such as the Fogarty International Center. Other organizations already making remarkable contributions in global health (GH) outreach are Médicins Sans Frontières, the Bill and Melinda Gates Foundation and several other mainly US-based research agencies, working “in convergence” with academia and industry to resolve GH care challenges. Promotion of emerging GH partnerships between cancer care organizations in high-income countries (HICs) and LMICs promises to impact positively on the control of cancer and HIV/AIDS globally. Innovations are required in promoting resource-setting appropriate access to universal health coverage and supportive human resources development, while exploring ways to engage the political class to comprehend the basis of, and need for the control of factors that are responsible for premature death and suffering among their people. LMICs need vigorous advocacy of science as an instrument of human development, for the conquest of poverty and the containment of the ravages of diseases, so as to ensure the global dissemination of the US cancer Moonshot, and UNAID 90-90-90 goals.


Global fund Moonshot UNAIDS UHC 90-90-90 Convergence Global health GAVI NCCN Obio 


  1. 1.
    WHO. The world health report 2000: health systems: improving performance. Geneva: World Health Organization; 2000.Google Scholar
  2. 2.
    Jamison DT, Summers LH, Alleyne G, Arrow KJ, Berkley S, Binagwaho A, et al. Global health 2035: a world converging within a generation. Lancet. 2013;382(9908):1898–955.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Beaglehole R, Bonita R, Alleyne G, Horton R, Li L, Lincoln P, et al. UN high-level meeting on non-communicable diseases: addressing four questions. Lancet. 2011;378(9789):449–55.PubMedCrossRefPubMedCentralGoogle Scholar
  4. 4.
    IHME. Institute for Health Metrics and Evaluation, development assistance for health database 1990–2015 (IHME, Seattle, WA, 2016). Seattle: Institute for Health Metrics and Evaluation, Development Assistance for Health Database; 2015. Available from:
  5. 5.
    Sachs JD, Schmidt-Traub G. Global fund lessons for sustainable development goals. Science. 2017;356(6333):32–3.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    GF. GF, “The right side of the tipping point for AIDS, tuberculosis and malaria: investment case for the Gobal Fund’s 217–2019 replenishment”. Geneva: Global Fund; 2015.Google Scholar
  7. 7.
    Group TAS. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;2015(373):808–22.Google Scholar
  8. 8.
    Bornemisza O, Bridge J, Olszak-Olszewski M, Sakvarelidze G, Lazarus J. Health aid governance in fragile states: the Global Fund experience. Glob Health Gov. 2010;4(1)Google Scholar
  9. 9.
    Nahlen BL, Low-Beer D. Building to collective impact: the Global Fund support for measuring reduction in the burden of malaria. Am J Trop Med Hyg. 2007;77(6 Suppl):321–7.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    WHO. WHO releases new guidance on insecticide-treated mosquito nets (press release). Geneva: World Health Organization; 2007. Available from:
  11. 11.
    Samb B, Desai N, Nishtar S, Mendis S, Bekedam H, Wright A, et al. Prevention and management of chronic disease: a litmus test for health-systems strengthening in low-income and middle-income countries. Lancet. 2010;376(9754):1785–97.PubMedCrossRefPubMedCentralGoogle Scholar
  12. 12.
    Sherry J, Mookherji S, Ryan L. The five-year evaluation of the Global Fund to fight AIDS, tuberculosis, and malaria: synthesis of study areas 1, 2 and 3. Geneva: GFATM and Macro International; 2009.Google Scholar
  13. 13.
    Smith L. Man’s inhumanity to man’and other platitudes of avoidance and misrecognition: an analysis of visitor responses to exhibitions marking the 1807 bicentenary. Mus Soc. 2010;8(3):193–214.Google Scholar
  14. 14.
    Piot P. Ebola’s perfect storm. Science. 2014;345(6202):1221.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
  16. 16.
    GAVI-Alliance. GAVI Alliance. Human pappilomavirus vaccine support. Oct 16, 2013. 2013. Available from: Accessed 22 Apr 2017.
  17. 17.
    Hadler SC, Fuqiang C, Averhoff F, Taylor T, Fuzhen W, Li L, et al. The impact of hepatitis B vaccine in China and in the China GAVI project. Vaccine. 2013;31:J66–72.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    ten Haaf K, Tammemägi MC, Bondy SJ, van der Aalst CM, Gu S, McGregor SE, et al. Performance and cost-effectiveness of computed tomography lung cancer screening scenarios in a population-based setting: a microsimulation modeling analysis in Ontario. Can PLoS Med. 2017;14(2):e1002225.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Hunter DJ, Frumkin H, Jha A. Preventive medicine for the planet and its peoples. N Engl J Med. 2017;376(17):1605–7.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Plotkin SA, Mahmoud AA, Farrar J. Establishing a global vaccine-development fund. N Engl J Med. 2015;373(4):297–300.PubMedCrossRefPubMedCentralGoogle Scholar
  21. 21.
    Clifford GM, Goncalves MAG, Franceschi S. HPV, group Hs. Human papillomavirus types among women infected with HIV: a meta-analysis. AIDS. 2006;20(18):2337–44.CrossRefGoogle Scholar
  22. 22.
    UNICEF. State of the world’s children: celebrating 20 years of the Convention on the Rights of the Child. New York: Unicef; 2009.Google Scholar
  23. 23.
    CA. Mapping the barriers to vaccination. Science. 2016;353(6307):1511.Google Scholar
  24. 24.
    de Figueiredo A, Johnston IG, Smith DM, Agarwal S, Larson HJ, Jones NS. Forecasted trends in vaccination coverage and correlations with socioeconomic factors: a global time-series analysis over 30 years. Lancet Glob Health. 2016;4(10):e726–e35.PubMedCrossRefPubMedCentralGoogle Scholar
  25. 25.
    Chen K. To run where the brave dare not go. Science. 2014;346(6215):1304.CrossRefGoogle Scholar
  26. 26.
    Fox RC. Doctors without borders: humanitarian quests, impossible dreams of Médecins Sans Frontières. Baltimore: JHU Press; 2014.Google Scholar
  27. 27.
    Campion EW. Treating millions for HIV—the adherence clubs of Khayelitsha. N Engl J Med. 2015;372(4):301–3.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Baltimore D. The boldness of philanthropists. Science. 2016;10(1126):1473.CrossRefGoogle Scholar
  29. 29.
    Fauci AS, Collins FS. Benefits and risks of influenza research: lessons learned. Science. 2012;336(6088):1522–3.PubMedPubMedCentralCrossRefGoogle Scholar
  30. 30.
    NIH. Fogarty International Center, Fogarty’s role in global health. 2017. Available from:
  31. 31.
    Sharp P, Jacks T, Hockfield S. Capitalizing on convergence for health care. Science. 2016;352(6293):1522–3.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Sharp P, Hockfield S. Convergence: the future of health. Science. 2017;355(6325):589.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Coates RJ, Bransfield DD, Wesley M, Hankey B, Eley JW, Greenberg RS, et al. Differences between black and white women with breast cancer in time from symptom recognition to medical consultation. Black/white cancer survival study group. J Natl Cancer Inst. 1992;84(12):938–50.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Janes CR, Corbett KK. Anthropology and global health. Annu Rev Anthropol. 2009;38:167–83.CrossRefGoogle Scholar
  35. 35.
    De Cock KM, Simone PM, Davison V, Slutsker L. The new global health. Emerg Infect Dis. 2013;19(8):1192–7.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Berlinguer G. Globalization and global health. Int J Health Serv. 1999;29(3):579–95.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Dwyer J. Global health and justice. Bioethics. 2005;19(5–6):460–75.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Schulman L. Recognizing global oncology as an academic field. Annual Conference of the American Society of Clinical Oncology. Chicago, IL; 2017 (Personal communication).Google Scholar
  39. 39.
    Trimble E. Global Health: it’s not about geography, it’s about perspectives. Annual Conference of the American Society of Clinical Oncology, Chicago, IL; 2017 (Personal communication).Google Scholar
  40. 40.
    Howlader N, Noone A, Krapcho M, Garshell J, Miller D, Altekruse S, et al. SEER Cancer Statistics Review, 1975–2012, National Cancer Institute. Bethesda. 2015.
  41. 41.
    Alatise OI. Key principles to strengthening partnerships. Meeting of the African Organisation for Research and Training in Cancer, North America Region, at the Annual Conference of the American Society of Clinical Oncology, Hilton Chicago, June 3rd, 2017 (personal communication).Google Scholar
  42. 42.
    Carlson RW, Scavone JL, Koh W-J, McClure JS, Greer BE, Kumar R, et al. NCCN framework for resource stratification: a framework for providing and improving global quality oncology care. J Natl Compr Cancer Netw. 2016;14(8):961–9.CrossRefGoogle Scholar
  43. 43.
    WHO. The world health report: working together for health. 2006. Available from:
  44. 44.
    Beyene T, Hoek H, Zhang Y, Vos T. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  45. 45.
    Fromer MJ. Cancer care in low-resource areas: some improvements over the years, but serious problems remain. The ASCO Post. December 10, 2015.Google Scholar
  46. 46.
    Abubakar I, Tillmann T, Banerjee A. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117–71.CrossRefGoogle Scholar
  47. 47.
    Nugent R, Feigl A. Where have all the donors gone? Scarce donor funding for non-communicable diseases. Washington, DC: Center for Global Development; 2010.Google Scholar
  48. 48.
    Anderson BO, Duggan C. Resource-stratified guidelines for cancer management: correction and commentary. J Glob Oncol. 2016;3:84–8. JGO006213PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Anderson BO, Braun S, Carlson RW, Gralow JR, Lagios MD, Lehman C, et al. Overview of breast health care guidelines for countries with limited resources. Breast J. 2003;9(s2):S42–50.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Anderson BO, Shyyan R, Eniu A, Smith RA, Yip CH, Bese NS, et al. Breast cancer in limited-resource countries: an overview of the breast health global initiative 2005 guidelines. Breast J. 2006;12(s1):S3–S15.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Echavarria MI, Anderson BO, Duggan C, Thompson B. Global uptake of BHGI guidelines for breast cancer. Lancet Oncol. 2014;15(13):1421–3.PubMedCrossRefPubMedCentralGoogle Scholar
  52. 52.
    Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, et al. Management and care of women with invasive cervical cancer: American Society of Clinical Oncology resource-stratified clinical practice guideline. J Glob Oncol. 2016;2(5):311–40.PubMedPubMedCentralCrossRefGoogle Scholar
  53. 53.
    Hirte H, Kennedy E, Elit L, Fung MFK. Systemic therapy for recurrent, persistent, or metastatic cervical cancer: a clinical practice guideline. Curr Oncol. 2015;22(3):211–9.PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Elit L, Kennedy E, Fyles A, et al. Follow-up for cervical cancer. 2015. Available from:
  55. 55.
    Colombo N, Carinelli S, Colombo A, Marini C, Rollo D, Sessa C, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii27–32.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Ebina Y, Yaegashi N, Katabuchi H, Nagase S, Udagawa Y, Hachisuga T, et al. Japan Society of Gynecologic Oncology guidelines 2011 for the treatment of uterine cervical cancer. Int J Clin Oncol. 2015;20(2):240–8.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Koh W-J, Greer BE, Abu-Rustum NR, Apte SM, Campos SM, Chan J, et al. Cervical cancer. J Natl Compr Cancer Netw. 2013;11(3):320–43.CrossRefGoogle Scholar
  58. 58.
    WHO. Comprehensive cervical cancer control: a guide to essential practice. 2nd ed. Available from:
  59. 59.
    Arrossi S, Temin S, Garland S, Eckert LON, Bhatla N, Castellsagué X, et al. Primary prevention of cervical cancer: American Society of Clinical Oncology resource-stratified guideline. J Glob Oncol. 2017:JGO. 2016.008151.Google Scholar
  60. 60.
    Horton S, Gauvreau CL. Cancer in low-and middle-income countries: an economic overview. In: Gelbrand H, Jha P, Sankaranarayanan R, et al., editors. Cancer: disease control priorities, vol. 3. Washington, DC: International Bank for Reconstruction and Development/World Bank; 2015. p. 263–80.Google Scholar
  61. 61.
    WHO. World Health Organization: new WHO guide to prevent and control cervical cancer. World Health Organization. 2014. Available from:
  62. 62.
    Fesenfeld M, Hutubessy R, Jit M. Cost-effectiveness of human papillomavirus vaccination in low and middle income countries: a systematic review. Vaccine. 2013;31(37):3786–804.PubMedCrossRefPubMedCentralGoogle Scholar
  63. 63.
    Castle PE, Jeronimo J, Temin S, Shastri SS. Screening to prevent invasive cervical cancer: ASCO resource-stratified clinical practice guideline. J Clin Oncol. 2017;35(11):1250–2.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    IARC. IARC handbooks of cancer prevention, Cervix cancer screening, vol. 10. Lyon: International Agency for Cancer Research; 2005.Google Scholar
  65. 65.
    Bruni L, Diaz M, Barrionuevo-Rosas L, Herrero R, Bray F, Bosch FX, et al. Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis. Lancet Glob Health. 2016;4(7):e453–e63.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the advisory committee on immunization practices (ACIP). Methods. 2007;12:15.Google Scholar
  67. 67.
    Shastri SS, Mittra I, Mishra GA, Gupta S, Dikshit R, Singh S, et al. Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 2014;106(3):dju009.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, et al. Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis. Lancet Oncol. 2014;15(2):172–83.PubMedCrossRefPubMedCentralGoogle Scholar
  69. 69.
    Arrossi S, Thouyaret L, Herrero R, Campanera A, Magdaleno A, Cuberli M, et al. Effect of self-collection of HPV DNA offered by community health workers at home visits on uptake of screening for cervical cancer (the EMA study): a population-based cluster-randomised trial. Lancet Glob Health. 2015;3(2):e85–94.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Castle PE, Rausa A, Walls T, Gravitt PE, Partridge EE, Olivo V, et al. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev Med. 2011;52(6):452–5.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Adesina A, Chumba D, Nelson AM, Orem J, Roberts DJ, Wabinga H, et al. Improvement of pathology in sub-Saharan Africa. Lancet Oncol. 2013;14(4):e152–e7.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Sayed S, Lukande R, Fleming KA. Providing pathology support in low-income countries. Alexandria: American Society of Clinical Oncology; 2015.Google Scholar
  73. 73.
    Olmsted SS, Moore M, Meili RC, Duber HC, Wasserman J, Sama P, et al. Strengthening laboratory systems in resource-limited settings. Am J Clin Pathol. 2010;134(3):374–80.PubMedCrossRefPubMedCentralGoogle Scholar
  74. 74.
    Sankaranarayanan R, Anorlu R, Sangwa-Lugoma G, Denny LA. Infrastructure requirements for human papillomavirus vaccination and cervical cancer screening in sub-Saharan Africa. Vaccine. 2013;31:F47–52.PubMedCrossRefPubMedCentralGoogle Scholar
  75. 75.
    Chuang LT, Feldman S, Nakisige C, Temin S, Berek JS. Management and care of women with invasive cervical cancer: ASCO resource-stratified clinical practice guideline. J Clin Oncol. 2016;34(27):3354–5.PubMedCrossRefPubMedCentralGoogle Scholar
  76. 76.
    Jeronimo J, Castle PE, Temin S, Denny L, Gupta V, Kim JJ, et al. Secondary prevention of cervical cancer: ASCO resource-stratified clinical practice guideline. J Glob Oncol. 2016;3(5):635–57. JGO006577PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    HVO. Health voluunter overseas Washington, DC. 2017. Available from:
  78. 78.
    GHWA. Global Health Workforce Alliance. 2017. Available from:
  79. 79.
    Chuang L, Moore KN, Creasman WT, Goodman A, Cooper HH, Price FV, et al. Teaching gynecologic oncology in low resource settings: a collaboration of health volunteers overseas and the society of gynecologic oncology: Elsevier; 2014.Google Scholar
  80. 80.
    IGCS. The gynecologic oncology global curriculum & mentorship program. Louisville: International Gynecologic Cancer Society; 2017. Available from: Google Scholar
  81. 81.
    ASCO. International professional development opportunities. Alexandria: American Society of Clinical Oncology; 2017. Available from: Google Scholar
  82. 82.
    ASCO. Conquer cancer foundation supports oncologists and patients with cancer worldwide. ASCO Daily News, May 29, 2015:44
  83. 83.
    ASCO. Multidisciplinary cancer management courses improve cancer care worldwide. ASCO Daily News, May 31, 2015:35
  84. 84.
    Shulman LN, Trimble E, Enui A, editors. Recognizing global oncology as an academic field. In: Annual conference of the American Society of Clinical Oncology, Chicago, IL, USA. 2017.Google Scholar
  85. 85.
    Gao GF, Feng Y. On the ground in Sierra Leone. Science. 2014;346(6209):666.PubMedCrossRefPubMedCentralGoogle Scholar
  86. 86.
    Sachs JD. From millennium development goals to sustainable development goals. Lancet. 2012;379(9832):2206–11.PubMedCrossRefPubMedCentralGoogle Scholar
  87. 87.
    Mehl G, Labrique A. Prioritizing integrated mHealth strategies for universal health coverage. Science. 2014;345(6202):1284–7.PubMedCrossRefPubMedCentralGoogle Scholar
  88. 88.
    UNGAS. The UN general assembly, 67/81 Global Health and Foreign Policy. United Nations, New York. 2012.Google Scholar
  89. 89.
    WHO. World Health report: health systems financing: the path to universal coverage. Geneva. 2010.Google Scholar
  90. 90.
    Gupta V, Kerry VB, Goosby E, Yates R. Politics and universal health coverage – the post-2015 global health agenda. N Engl J Med. 2015;373(13):1189–92.PubMedCrossRefPubMedCentralGoogle Scholar
  91. 91.
    WHO. World Health Assembly Resolution WHA 58.22, May 2005. Accessed 26 June 2017.
  92. 92.
    WHO. Global status report on non-communicable diseases 2010, Geneva. 2011.Google Scholar
  93. 93.
    WHO. Global Health Observatory data repository: NCD country capacity survey 2010. Geneva: World Health Organization; 2010. Available from: Google Scholar
  94. 94.
    Stefan DC, Elzawawy AM, Khaled HM, Ntaganda F, Asiimwe A, Addai BW, et al. Developing cancer control plans in Africa: examples from five countries. Lancet Oncol. 2013;14(4):e189–e95.PubMedCrossRefPubMedCentralGoogle Scholar
  95. 95.
    Reich MR, Shibuya K. The future of Japan’s health system – sustaining good health with equity at low cost. N Engl J Med. 2015;373(19):1793–7.PubMedCrossRefPubMedCentralGoogle Scholar
  96. 96.
    WHO. Countdown to 2015 decade report. Nigeria: World Health Organization/World Bank; 2015. Available from: Google Scholar
  97. 97.
    Reddy KS. India’s aspirations for universal health coverage. N Engl J Med. 2015;373(1):1–5.PubMedCrossRefPubMedCentralGoogle Scholar
  98. 98.
    Sanou B. The world in 2013: ICT facts and figures. Geneva: International Telecommunications Union; 2013.Google Scholar
  99. 99.
    Organization WH. The partnership for maternal, newborn & child health. A global review of the key interventions related to reproductive, maternal, newborn and child health (Rmnch). Geneva: PMNCH; 2011. 2017Google Scholar
  100. 100.
    Labrique AB, Vasudevan L, Kochi E, Fabricant R, Mehl G. mHealth innovations as health system strengthening tools: 12 common applications and a visual framework. Glob Health Sci Pract. 2013;1(2):160–71.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Moobilevrs. Uganda Registration Services Bureau, Mobile Vital Records System. Available from:
  102. 102.
    Campbell J, Buchan J, Cometto G, David B, Dussault G, Fogstad H, et al. Human resources for health and universal health coverage: fostering equity and effective coverage. Bull World Health Organ. 2013;91(11):853–63.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Mwanahamuntu MH, Sahasrabuddhe VV, Kapambwe S, Pfaendler KS, Chibwesha C, Mkumba G, et al. Advancing cervical cancer prevention initiatives in resource-constrained settings: insights from the cervical cancer prevention program in Zambia. PLoS Med 2011;8(5):e1001032.PubMedPubMedCentralCrossRefGoogle Scholar
  104. 104.
    Suri T, Jack W. The long-run poverty and gender impacts of mobile money. Science. 2016;354(6317):1288–92.PubMedCrossRefPubMedCentralGoogle Scholar
  105. 105.
    Corby N. Using mobile finance to reimburse sexual and reproductive health vouchers in Madagascar. London: Marie Stopes International; 2012.Google Scholar
  106. 106.
    Holmes D. Margaret Chan: committed to universal health coverage. Lancet. 2012;380(9845):879.PubMedCrossRefPubMedCentralGoogle Scholar
  107. 107.
    Fakunle B. Obio community health model “wipes away tears” in Nigeria [Internet]. VOICES: Ideas and Insight From Explorers, July 2, 2015.Google Scholar
  108. 108.
    Sudhinaraset M, Ingram M, Lofthouse HK, Montagu D. What is the role of informal healthcare providers in developing countries? A systematic review. PLoS One. 2013;8(2):e54978.PubMedPubMedCentralCrossRefGoogle Scholar
  109. 109.
    Das J, Holla A, Das V, Mohanan M, Tabak D, Chan B. In urban and rural India, a standardized patient study showed low levels of provider training and huge quality gaps. Health Aff. 2012;31(12):2774–84.CrossRefGoogle Scholar
  110. 110.
    Powell-Jackson T. A pragmatic way forward? Science. 2016;354(6308):34–5.PubMedCrossRefPubMedCentralGoogle Scholar
  111. 111.
    GovernmentofIndia. Ministry of Health and Family Welfare, Government of India, National Health Policy 2015 Draft, December 2014. Available from:
  112. 112.
    Mackintosh M, Channon A, Karan A, Selvaraj S, Cavagnero E, Zhao H. What is the private sector? Understanding private provision in the health systems of low-income and middle-income countries. Lancet. 2016;388(10044):596–605.PubMedCrossRefPubMedCentralGoogle Scholar
  113. 113.
    Das J, Chowdhury A, Hussam R, Banerjee AV. The impact of training informal health care providers in India: a randomized controlled trial. Science. 2016;354(6308):aaf7384.PubMedCrossRefPubMedCentralGoogle Scholar
  114. 114.
    Haines A, Kuruvilla S, Borchert M. Bridging the implementation gap between knowledge and action for health. Bull World Health Organ. 2004;82(10):724–31.PubMedPubMedCentralGoogle Scholar
  115. 115.
    Cockcroft A, Masisi M, Thabane L, Andersson N. Legislators learning to interpret evidence for policy. Science. 2014;345(6202):1244–5.PubMedCrossRefPubMedCentralGoogle Scholar
  116. 116.
    Evipnet. Report on International Forum on evidence informed health policy in low- and middle-income countries, Addis Ababa, Ethiopia, 27 to 31 August 2012.
  117. 117.
    Tovey CA. In defense of basic research. American Association for the Advancement of Science. 2017.Google Scholar
  118. 118.
    Flexner A. The usefulness of useless knowledge. Princeton: Princeton University Press; 2017.CrossRefGoogle Scholar
  119. 119.
    Alberts B. Editorial. Science for life. Science. 2017;355(6332):1353.PubMedCrossRefPubMedCentralGoogle Scholar
  120. 120.
    Mgwebi T. Three Q’s. 2015. Available from: Google Scholar
  121. 121.
    Nattrass N. Mortal combat: AIDS denialism and the struggle for antiretrovirals in South Africa. Scottsville: University of KwaZulu-Natal Press; 2007.Google Scholar
  122. 122.
    Jamison DT, Breman JG, Measham AR, Alleyne G, Claeson M, Evans DB, et al. Disease control priorities in developing countries. New York/Washington, DC: Oxford University Press/World Bank; 2006.Google Scholar
  123. 123.
    Carney JP. Science advocacy, defined. Science. 2014;345(6194):243.PubMedCrossRefPubMedCentralGoogle Scholar
  124. 124.
    Houston OR. We have a narrative: why science needs story. Chicago: University of Chicago Press; 2015.Google Scholar
  125. 125.
    Luna RE. The storytelling scientist. Washington, DC: American Association for the Advancement of Science; 2015. p. 391.Google Scholar
  126. 126.
    NAN. Schools nationwide to teach maths, science subjects in indigenous languages – minister. Punch, May 31, 2017.Google Scholar
  127. 127.
    Akhampapa. Nigerian schools will start teaching maths, science in local dialect soon – minister 2017. Available from:
  128. 128.
    Scagliotti GV, Parikh P, Von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non–small-cell lung cancer. J Clin Oncol. 2008;26(21):3543–51.PubMedCrossRefPubMedCentralGoogle Scholar
  129. 129.
    Lee BG. KIST at 50, beyond the miracle. American Association for the Advancement of Science. 2016.Google Scholar
  130. 130.
    Mtingwa SK, Winick H. SESAME and beyond. Washington, DC American Association for the Advancement of Science. 2017.Google Scholar
  131. 131.
    Pastrana SJ. Science in US-Cuba relations. Science. 2015;348(6236):735.PubMedCrossRefPubMedCentralGoogle Scholar
  132. 132.
    Finlay CJ. Yellow fever: Oliver and Boyd; 1894.Google Scholar
  133. 133.
    Stone R. In from the cold. After keeping science alive during decades of scarcity, Cuba’s “guerilla scientists” are ready to rejoin the world. Science. 2015;348(6236):746–51.PubMedCrossRefPubMedCentralGoogle Scholar
  134. 134.
    Singapore. Singapore boosts science. Science. 2016;351(6270):209.Google Scholar
  135. 135.
    NewDelhi. India eyes Mars and Venus. Science. 2017;355(6327):779. Google Scholar
  136. 136.
    Niemeier D, Gombachika H, Richards-Kortum R. How to transform the practice of engineering to meet global health needs. Science. 2014;345(6202):1287–90.PubMedCrossRefPubMedCentralGoogle Scholar
  137. 137.
    Horton R, Beaglehole R, Bonita R, Raeburn J, McKee M, Wall S. From public to planetary health: a manifesto. Lancet. 2014;383(9920):847.PubMedCrossRefPubMedCentralGoogle Scholar
  138. 138.
    IOM. Institute of Medicine. Evaluation of PEPFAR. Washington, DC: National Academies Press; 2013.Google Scholar
  139. 139.
    Baldinger P, Ratterman W. Powering health: options for improving energy services at health facilities in Ethiopia. Washington, DC: USAID; 2008.Google Scholar
  140. 140.
    Frost LJ, Reich MR. Access: how do good health technologies get to poor people in poor countries?: Harvard Center for Population and Development Studies; 2008.Google Scholar
  141. 141.
    Richards-Kortum R, Gray LV, Oden M. Engaging undergraduates in global health technology innovation. Science. 2012;336(6080):430–1.PubMedCrossRefPubMedCentralGoogle Scholar
  142. 142.
    Aker JC, Mbiti IM. Mobile phones and economic development in Africa. J Econ Perspect. 2010;24(3):207–32.CrossRefGoogle Scholar
  143. 143.
    Sciencemag. Low-cost x-rays for all. Science. 2015;347(6227):1180–1.CrossRefGoogle Scholar
  144. 144.
    Stone R. Graying Cuba strains socialist safety net. Science. 2015;348(6236):750.PubMedCrossRefPubMedCentralGoogle Scholar
  145. 145.
    Holmes J, Jones B, Heap B. Smart villages. Science. 2015;350(6259):359.PubMedCrossRefPubMedCentralGoogle Scholar
  146. 146.
    Sambo AS. Strategic developments in renewable energy in Nigeria. International Association for Energy Economics. 2009;16(3):15–9.Google Scholar
  147. 147.
    Wu Z. HIV/AIDS in China: beyond the numbers: Springer; 2017.Google Scholar
  148. 148.
    Harper K. The aftermath of AIDS in China: American Association for the Advancement of Science; 2016.Google Scholar
  149. 149.
    Sporn MB. The war on cancer. Lancet. 1996;347(9012):1377–81.PubMedCrossRefPubMedCentralGoogle Scholar
  150. 150.
    Kesselheim AS, Avorn J. New “21st century cures” legislation: speed and ease vs science. JAMA. 2017;317(6):581–2.PubMedCrossRefPubMedCentralGoogle Scholar
  151. 151.
    Kaiser J, Couzin-Frankel J. Biden seeks clear course for his cancer moonshot. Science. 2016;351(6271):325–6.PubMedCrossRefPubMedCentralGoogle Scholar
  152. 152.
    Singer DS, Jacks T, Jaffee E. A US “Cancer moonshot” to accelerate cancer research. Science. 2016;353(6304):1105–6.PubMedCrossRefPubMedCentralGoogle Scholar
  153. 153.
    Cavallo J. Cancer moonshot blue ribbon panel recommends 10 ways to speed cancer advances. The ASCO Post. 2016 September 25;2016:72.Google Scholar
  154. 154.
    Corsi DJ, Boyle MH, Lear SA, Chow CK, Teo KK, Subramanian S. Trends in smoking in Canada from 1950 to 2011: progression of the tobacco epidemic according to socioeconomic status and geography. Cancer Causes Control. 2014;25(1):45–57.PubMedCrossRefPubMedCentralGoogle Scholar
  155. 155.
    StatisticsCanada. Statistics Canada 2011. Canadian Community Health Survey (CCHS), Cycle 1.1, 2.1, 3.1, 4.1 and 2008, 2009, 2010 Annual Component surveys (Microdata. Ottawa, Ontario: Statistics Canada Health Statistics Division (producer and distributor): Ottawa Ontario: Data Liberation Initiative (distributor); 2011.Google Scholar
  156. 156.
    CancerCareOntario. Cancer Fact: Lung Cancer accounts for largest proportion of premature Ontario cancer deaths. Available from:
  157. 157.
    Field JK, Oudkerk M, Pedersen JH, Duffy SW. Prospects for population screening and diagnosis of lung cancer. Lancet. 2013;382(9893):732–41.PubMedCrossRefPubMedCentralGoogle Scholar
  158. 158.
    Sox HC. Better evidence about screening for lung cancer. Mass Medical Soc. 2011.Google Scholar
  159. 159.
    Moyer VA. Screening for lung cancer: US preventive services task force recommendation statement. Ann Intern Med. 2014;160(5):330–8.PubMedCrossRefPubMedCentralGoogle Scholar
  160. 160.
    McMahon PM, Kong CY, Bouzan C, Weinstein MC, Cipriano LE, Tramontano AC, et al. Cost-effectiveness of computed tomography screening for lung cancer in the United States. J Thorac Oncol. 2011;6(11):1841–8.PubMedPubMedCentralCrossRefGoogle Scholar
  161. 161.
    Pyenson BS, Sander MS, Jiang Y, Kahn H, Mulshine JL. An actuarial analysis shows that offering lung cancer screening as an insurance benefit would save lives at relatively low cost. Health Aff. 2012;31(4):770–9.CrossRefGoogle Scholar
  162. 162.
    Mahadevia PJ, Fleisher LA, Frick KD. Eng J, Goodman SN, Powe NR. Lung cancer screening with helical computed tomography in older adult smokers: a decision and cost-effectiveness analysis. JAMA. 2003;289(3):313–22.PubMedCrossRefPubMedCentralGoogle Scholar
  163. 163.
    Goffin JR, Flanagan WM, Miller AB, Fitzgerald NR, Memon S, Wolfson MC, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol. 2015;1(6):807–13.PubMedCrossRefPubMedCentralGoogle Scholar
  164. 164.
    Raymakers AJ, Mayo J, Lam S, Fitzgerald JM, Whitehurst DG, Lynd LD. Cost-effectiveness analyses of lung cancer screening strategies using low-dose computed tomography: a systematic review. Appl Health Econ Health Policy. 2016;14(4):409–18.PubMedCrossRefPubMedCentralGoogle Scholar
  165. 165.
    Fauci AS, Marston HD. Ending the HIV–AIDS pandemic – follow the science. N Engl J Med. 2015;373(23):2197–9.PubMedCrossRefPubMedCentralGoogle Scholar
  166. 166.
    Molina J-M, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.PubMedCrossRefPubMedCentralGoogle Scholar
  167. 167.
    START-GROUP. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;2015(373):795–807.CrossRefGoogle Scholar
  168. 168.
    Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis. 2014;14(4):281–90.PubMedPubMedCentralCrossRefGoogle Scholar
  169. 169.
    El-Sadr WM, Harripersaud K, Bayer R. End of AIDS – hype versus hope. Science. 2014;345(6193):166.PubMedCrossRefPubMedCentralGoogle Scholar
  170. 170.
    Barouch DH, Deeks SG. Immunologic strategies for HIV-1 remission and eradication. Science. 2014;345(6193):169–74.PubMedPubMedCentralCrossRefGoogle Scholar
  171. 171.
    Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997;278(5341):1295–300.PubMedCrossRefPubMedCentralGoogle Scholar
  172. 172.
    Persaud D, Zhou Y, Siliciano JM, Siliciano RF. Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol. 2003;77(3):1659–65.PubMedPubMedCentralCrossRefGoogle Scholar
  173. 173.
    Chun T-W, Stuyver L, Mizell SB, Ehler LA, Mican JAM, Baseler M, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci. 1997;94(24):13193–7.PubMedCrossRefPubMedCentralGoogle Scholar
  174. 174.
    Chun T-W, Engel D, Berrey MM, Shea T, Corey L, Fauci AS. Early establishment of a pool of latently infected, resting CD4+ T cells during primary HIV-1 infection. Proc Natl Acad Sci. 1998;95(15):8869–73.PubMedCrossRefPubMedCentralGoogle Scholar
  175. 175.
    Chun T-W, Carruth L, Finzi D, Shen X. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387(6629):183–8.PubMedCrossRefPubMedCentralGoogle Scholar
  176. 176.
    Chun T-W, Davey RT, Engel D, Lane HC, Fauci AS. AIDS: re-emergence of HIV after stopping therapy. Nature. 1999;401(6756):874–5.PubMedCrossRefPubMedCentralGoogle Scholar
  177. 177.
    Finzi D, Blankson J, Siliciano JD, Margolick JB, Chadwick K, Pierson T, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5(5):512–7.PubMedCrossRefPubMedCentralGoogle Scholar
  178. 178.
    Ho Y-C, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155(3):540–51.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Christopher Kwesi O. Williams
    • 1
  1. 1.Hematology Oncology ConsultancyPort AngelesUSA

Personalised recommendations